ICU Medical (NASDAQ:ICUI) Updates FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.750-8.450 for the period, compared to the consensus earnings per share estimate of 7.410. The company issued revenue guidance of -.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $157.03 on Friday. The firm’s fifty day simple moving average is $149.40 and its 200 day simple moving average is $135.87. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of 7,855.43 and a beta of 0.79. ICU Medical has a twelve month low of $107.00 and a twelve month high of $164.35. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.37% and a net margin of 0.03%.The business had revenue of $535.94 million for the quarter, compared to analysts’ expectations of $541.20 million. During the same quarter in the previous year, the firm posted $2.11 earnings per share. The company’s revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts expect that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday. KeyCorp increased their price target on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q4 EPS beat street estimates — ICU Medical reported $1.91 EPS vs. the consensus $1.68, a surprise on the bottom line that helped lift sentiment. Earnings and Revenues Surpass Estimates
• Positive Sentiment: Company raised FY2026 EPS guidance to a range of $7.75–$8.45, above the consensus ~7.41, signaling confidence in the outlook and likely supporting the rally. Company Press Release
• Positive Sentiment: Sell-side support: Piper Sandler reiterated a Buy rating, which can sustain investor demand following results. Piper Sandler Rating
• Neutral Sentiment: Board action to extend an executive severance plan was announced as a measure to preserve leadership stability — governance/retention detail that reduces execution risk but is not a direct earnings driver. Severance Plan Extension
• Neutral Sentiment: Company published the earnings slide deck and call transcript for investors to review management commentary and details on margins, supply chain and demand trends. Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed expectations at $535.94M vs. $541.20M est. and was down ~14% year‑over‑year, highlighting ongoing demand weakness that investors will watch for reversal. Q4 Results and Guidance
• Negative Sentiment: Profitability pressure: EPS declined from $2.11 a year ago to $1.91 and the company reported a slightly negative net margin, underscoring margin and volume headwinds. Investor Presentation / Press Release

Institutional Investors Weigh In On ICU Medical

Several large investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its stake in ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. Headlands Technologies LLC bought a new stake in shares of ICU Medical in the 2nd quarter valued at about $177,000. O Shaughnessy Asset Management LLC bought a new stake in ICU Medical in the fourth quarter valued at approximately $203,000. Panagora Asset Management Inc. acquired a new stake in shares of ICU Medical during the 4th quarter worth about $205,000. Finally, Janney Montgomery Scott LLC bought a new stake in shares of ICU Medical during the fourth quarter worth approximately $216,000. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.